Privo Technologies, Inc. Receives IRB Approval for PRV211- Intraoperative Chemotherapy Treatment for Solid Tumors
Privo Technologies, Inc. is pleased to announce that it has received IRB approval for its CLN-004 study from WCG IRB. CLN-004 is a Phase 1/2, open-label, safety and efficacy study accessing the tolerability, anti-tumor effects, systemic exposure, and device technical effects of PRV211 (Cisplatin Intraoperative System) in Subjects with T2-T3 Oral Squamous Cell Carcinoma (OSCC) amenable to surgery. PRV211 is a sterilized derivative of the nano engineered PRV platform intended for intraoperative chemotherapy treatment for all solid tumor surgeries immediately following surgical excision. The goal is to treat the tumor bed locally, eliminating any remaining micro metastases or close margins that are unable to be fully resected while avoiding system circulation.
This is Privo’s 3rd IRB approval with WCG.
The WCG IRB, formally known as the WIRB Copernicus Group, Inc., is the industry leader in ethical review of clinical trial protocols with over 50 years of experience.
Privo Technologies, Inc. (Privo) is a phase 3 clinical-stage biopharmaceutical company committed to developing innovative therapeutics designed to eliminate cancers and prevent recurrence. Privo aims to provide better and more accessible treatment options to diverse patient populations around the world with the potential to transform standard of care for treating solid tumors. Privo is headquartered in Peabody, a suburb of Boston, Massachusetts. For more information on the technology see Privo’s most recent publication (https://www.nature.com/articles/s41467-022-31859-3), described in detail in Forbes: Disruptive Innovation In Drug Delivery Systems.
Privo’s lead asset, PRV111 has been shown to be effective in patients with head and neck cancer in several hospitals across the US during a safety and efficacy Phase I/II clinical study, dramatically reducing tumor volume without any systemic toxicity. For additional information on Privo Technologies, Inc. please visit www.privotechnologies.com.
Media Contact: firstname.lastname@example.org